Volume 29, Issue 156, February 2025

The role of GLP-1 analogues in the treatment of obesity in women with Polycystic Ovary Syndrome

Martyna Koszyk^1♦, Nikola Perchel², Zuzanna Kudas², Paweł Nowocin², Aleksandra Litwin², Karolina Krzywicka³, Dawid Wiktor Kulczyński², Natalia Dąbrowska², Paulina Kumięga², Piotr Wasiński²

¹Cardinal Stefan Wyszyński University in Warsaw, Kazimierza Wóycickiego 1/3, 01-938 Warsaw, Poland
²Medical University of Warsaw: Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
³SPKSO Ophthalmic University Hospital in Warsaw, Józefa Sierakowskiego 13, 03-709 Warszawa, Poland

^♦Corresponding Author
Cardinal Stefan Wyszyński University in Warsaw, Kazimierza Wóycickiego 1/3, 01-938 Warsaw, Poland

ABSTRACT

GLP-1 receptor agonists have newly appeared in the treatment for metabolic disorders of polycystic ovary syndrome (PCOS), including obesity and insulin resistance. It has got a lot of benefits, weight loss, increased insulin sensitivity, make better lipid profiles, regulars menstrual cycles. GLP-1 receptor agonists may offer better metabolic-endocrine effects than standard treatment, such as metformin. More research is needed to confirm safety and identify optimal treatment strategies, however. The review highlights the significance of GLP-1 receptor agonists for managing PCOS and suggests future research priorities.

Keywords: GLP-1 receptor, PCOS, metabolic, menstrual cycles

Medical Science, 2025, 29, e42ms3485

PDF

DOI: https://doi.org/10.54905/disssi.v29i156.e42ms3485

Published: 25 February 2025